VTE is a common complication of cancer and its therapy. Treatment of cancer-associated VTE is challenging, and the risks of recurrent thrombosis and bleeding are higher among patients with cancer than among those without cancer. These two complications are important because they contribute to mortality and morbidity and may interfere with cancer treatment and increase the risk of hospitalization.
The efficacy and safety of direct oral anticoagulants as compared with long-term low-molecular-weight heparin for the treatment of cancer-associated VTE have not been established. The Hokusai VTE Cancer trial was conducted to compare the oral factor Xa inhibitor edoxaban with subcutaneous dalteparin for the treatment of patients with cancer-associated VTE.